Aaron Ring
@aaronmring
Followers
9K
Following
19K
Media
177
Statuses
3K
Associate Professor at @FredHutch Studying #cytokines, (auto)antibodies, and #cancerimmunotherapy Founder: @SimchaTx, @Seranova, Stipple Bio, and @AriaxBio
Seattle, WA
Joined December 2017
T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below https://t.co/VgTByRKRCX
21
111
404
Exciting to see our collaboration with @Google highlighted here — using AI to generate and test new biological hypotheses!
An exciting milestone for AI in science: Our C2S-Scale 27B foundation model, built with @Yale and based on Gemma, generated a novel hypothesis about cancer cellular behavior, which scientists experimentally validated in living cells. With more preclinical and clinical tests,
13
18
298
https://t.co/LsgdwXEmFt Let's focus on how to increase speed and reduce cost of developing medicines -- there are lessons we can learn here from Chinese biotechs. @ldtimmerman
@NeilUdassi
timmermanreport.com
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting,...
3
2
29
Preparing PDB files for protein design usually means wrestling with PyMOL or ChimeraX. We're making it easier. Watch us use our new Prep Inputs feature to go from PDB fetch → structure trimming → hotspot selection → launching a design job in a leisurely 75 seconds.
2
9
52
Meet the latest Nobel Prize winner with Bay Area ties … https://t.co/gOEXmNouEy
bizjournals.com
Fred Ramsdell, co-founder of Sonoma Biotherapeutics, shares Nobel Prize for discoveries in immune system regulation and autoimmune disease prevention.
2
5
16
Should grand juries be instructed that they have an oath to the people and are REQUIRED to nullify unjust laws & hold officials accountable?
3
8
20
Excited for the @CartographyBio team! IMO developing the most innovative T cell engager therapeutics pipeline for cancers with high unmet need. Looking forward to partnering with our new investors, @scienceman2023 @pfizer, @Amgen, @LGE_Global, and others, and very grateful for
We're excited to share the close of our $67M Series B financing, which will enable us to advance our lead program into the clinic & continued acceleration of additional oncology programs from our drug discovery platforms. Our CEO shares more below. Details: https://t.co/OyqGLYqQO2
0
7
39
Bravo @ManifoldBio for releasing MBER, entirely open source to boot! We'll be spinning this up. https://t.co/65sz01Z1LE
biorxiv.org
Recent machine learning approaches have achieved high success rates in designing protein binders that demonstrate in vitro binding to their targets. While open models for unconstrained “minibinder”...
2
17
116
Another banger piece from Brian on antibody design. If you want to start using protein design tools, I highly recommend following the Boolean Biotech blog.
New blogpost on the latest in AI antibody design. Including some code to easily run Germinal and IgGM on modal! https://t.co/G2ZC6fzUxq
0
0
11
Engineering synthetic agonists for targeted activation of Notch signaling @nchembio @MoffittNews @vcluca1 🇺🇸 https://t.co/4V060nBqyK
0
3
19
Defense AI Stock @VWAVInc Holdings ( NASDAQ: $VWAV) Reports Strategic Collaboration with PVML News summary: VisionWave Holdings, Inc. (Nasdaq: VWAV), a defense technology company specializing in autonomous systems, has announced a strategic collaboration with PVML, a Tel
2
2
3
Go outside w a team Get exercise Give back A protocol for happiness :-) Thanks @ldtimmerman for bringing our community together throughout the year in such special ways Mount Katahdin, here we come! We're raising funds this time to support @DamonRunyon
2
2
23
FreeBindCraft has been a fun evening hobby project. Can PyRosetta be replaced in BindCraft with open-source alternatives? Answer: so far it seems to work great and runs considerably faster. Hopefully this can tide us over until @martinpacesa releases BindCraft2. PRs welcome!
FreeBindCraft brings open-source protein design to everyone. By replacing PyRosetta with MIT/BSD-licensed alternatives, BindCraft has been freed from its licensing constraints. Available now on Ariax! Read our announcement at
1
5
67
Major congrats to @MartinPacesa and the team. Let's get 1000+ citations for BindCraft now! 😎
Exciting to see our protein binder design pipeline BindCraft published in its final form in @Nature ! This has been an amazing collaborative effort with Lennart, @csche11h, @sokrypton, @befcorreia and many other amazing lab members and collaborators. https://t.co/PTMoqQqwcU
0
0
16
I'm now the proud owner of a bespoke, handcrafted 96 well magnetic separator designed by my Twitter BFF @AdrianoAguzzi. Thanks a million!!!
5
3
80
I turned chess into a video game: 40 players. Giant chessboard. ONE winner. Also, I added bombs💣 Playtest starts Oct 25th!
316
431
3K
BindCraft isn't just for miniproteins. A new preprint validates 47-67% success rates for BindCraft-derived peptides with nM affinities. Our tutorial with @MartinPacesa covers this work and walks through our new dedicated peptide interface. Read it here:
ariax.bio
Learn how to harness BindCraft's newly validated peptide design capabilities. From setup to optimization, master the art of creating high-affinity peptide binders for your therapeutic targets.
3
44
164
CAR-T cells against solid tumors. Listen to @sabahoney on The Long Run.
timmermanreport.com
Sabah Oney is today’s guest on The Long Run. Sabah is the CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics. This startup is developing engineered CAR-T cell therapies for solid...
1
1
7
Could the same proteins that drive autoimmune disease help fight cancer? In @Nature, Emerging Leader Award winner @aaronmring of @FredHutch shows that some autoantibodies are linked to better outcomes for patients receiving checkpoint inhibitor therapies. https://t.co/FYkYJ7cyTk
1
4
24
Chinese Hamster Ovary, or CHO cells, make roughly 70 percent of all F.D.A. approved biologics sold on the market. This includes bestsellers like Humira®, used to treat Crohn’s and rheumatoid arthritis, and Keytruda®, a cancer therapy. Despite their ubiquity in the pharmaceutical
1
21
105
Martin is a breakout star in the AI-powered protein design space. He led the effort to create BindCraft and he's just getting started. I can't think of a better lab to do a post-doc or contribute as professional research staff if you want to get into this space.
Thank you everyone for the congratulations and the large number of applications! I want to specifically encourage applications for these positions: * Postdoc in structural biology (cryoEM, ideally with X-ray too) * Full time lab manager/technician with wetlab experience
2
0
24
This month, the Big Ten Cancer Research Consortium highlights our member institution @fredhutch Cancer Center and Lawrence Fong, MD, who serves as scientific director of the Immunotherapy Integrated Research Center at Fred Hutch. Read more: https://t.co/3XPv6Ilsoj
0
5
14
Clone tracing T cell responses in cancer (using TCR-seq methods) has been incredibly valuable for understanding immunotherapy response and opportunities. A holy grail for us has been thinking about to achieve this for innate immune responses in human cancer - with high accuracy
For innate immune cells, the lack of diverse receptor rearrangements has prevented the study of clonal evolution of the innate immune system in human tissues and tumors. With @satpathology and @caleblareau, I’m delighted to share my PhD work that tackles this challenge:
2
4
46
Excellen nanomolar peptide binder design success rates with BindCraft!
Generative Design of High-Affinity Peptides Using BindCraft https://t.co/1N1Y9jQVbu
#biorxiv_biochem
0
4
32